| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Yohimbic acid targets alpha-2 adrenergic receptors (α₂-ARs). As a yohimbine metabolite and analogue, it inhibits α₂-adrenergic receptor activity. This inhibition leads to increased norepinephrine release and vasodilation. The compound also displays vasodilatory effects and may be utilized in osteoarthritis (OA) research.
|
|---|---|
| ln Vitro |
In vitro, Yohimbic acid monohydrate exhibits inhibitory activity on alpha-2 adrenergic receptors. As an amphoteric demethylated analogue of yohimbine, it displays vasodilatory effects. Its activity is assessed using receptor binding assays and functional assays measuring α₂-adrenergic receptor-mediated signaling and vasodilation.
|
| ln Vivo |
In vivo activity data for Yohimbic acid monohydrate are limited in the available literature. Its vasodilatory effects suggest potential applications in cardiovascular research. It may also be utilized in osteoarthritis (OA) research. Further in vivo studies are needed to characterize its efficacy and safety in animal models.
|
| Enzyme Assay |
In vitro receptor binding assays for Yohimbic acid monohydrate are performed using membrane preparations expressing alpha-2 adrenergic receptors. Radioligand competition binding assays are used to measure the compound's affinity for α₂-ARs. Functional assays measure the compound's ability to inhibit α₂-adrenergic receptor-mediated signaling, such as inhibition of cAMP accumulation or calcium mobilization.
|
| Cell Assay |
In vitro cellular assays for Yohimbic acid monohydrate are performed using cells expressing α₂-adrenergic receptors. Cells are treated with the compound, and receptor-mediated signaling is measured. Vasodilatory effects are assessed using isolated blood vessel preparations or endothelial cell assays measuring nitric oxide production and vasorelaxation.
|
| Animal Protocol |
In vivo animal experiments for Yohimbic acid monohydrate are not extensively documented. As a research compound, in vivo studies would typically involve administration to animal models of cardiovascular disease or osteoarthritis. The compound would be administered via appropriate routes, and efficacy would be assessed by measuring blood pressure, vascular function, or joint inflammation.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Yohimbic acid monohydrate have been characterized in part. The compound has a molecular weight of 358.43 and molecular formula C₂₀H₂₆N₂O₄·H₂O. It has a melting point of 267-268°C and is supplied with purity ≥99%. It appears as a solid. Further PK studies are needed to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Yohimbic acid monohydrate are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
Yohimbic acid monohydrate is an indole alkaloid derived from the bark of the Yohimbe tree (Pausinystalia yohimbe). It is a demethylated analogue of yohimbine that exhibits α₂-adrenergic receptor inhibitory activity and vasodilatory effects. It is used in pharmaceutical and biochemical research. This product is for research use only.
|
| Molecular Formula |
C20H26N2O4
|
|---|---|
| Molecular Weight |
358.43100
|
| Exact Mass |
358.189
|
| CAS # |
207801-27-2
|
| Related CAS # |
Yohimbic acid;522-87-2
|
| PubChem CID |
6419962
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
600ºC at 760 mmHg
|
| Melting Point |
267-268ºC (dec.)(lit.)
|
| Vapour Pressure |
3.04E-15mmHg at 25°C
|
| LogP |
2.432
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
26
|
| Complexity |
541
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1C[C@@H]([C@@H]([C@@H]2[C@@H]1CN3CCC4=C([C@@H]3C2)NC5=CC=CC=C45)C(=O)O)O.O
|
| InChi Key |
UXXCUDYYOMDFPX-GPRFVYSASA-N
|
| InChi Code |
InChI=1S/C20H24N2O3.H2O/c23-17-6-5-11-10-22-8-7-13-12-3-1-2-4-15(12)21-19(13)16(22)9-14(11)18(17)20(24)25;/h1-4,11,14,16-18,21,23H,5-10H2,(H,24,25);1H2/t11-,14-,16-,17-,18+;/m0./s1
|
| Chemical Name |
(1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid;hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 125 mg/mL (~348.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7899 mL | 13.9497 mL | 27.8995 mL | |
| 5 mM | 0.5580 mL | 2.7899 mL | 5.5799 mL | |
| 10 mM | 0.2790 mL | 1.3950 mL | 2.7899 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
